Molecular markers in malignant cutaneous melanoma: Gift horse or one-trick pony?

Steve R. Martinez, Dave S B Hoon

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The management of malignant cutaneous melanoma is problematic. Current clinical prognostic factors do not adequately predict disease recurrence and overall survival in a significant subset of patients. Adjuvant therapies for melanoma are notoriously toxic and associated with significant morbidity. Furthermore, it has been difficult to predict which patients will respond best to these treatments, if at all. DNA and RNA biomarkers have been developed to help overcome these problems. Biomarkers have been shown to upstage patients with melanoma, but are the assays sensitive and specific enough for clinical use as predictors of disease outcome or treatment response? We review our experience with DNA and RNA biomarkers in terms of their prognostic and predictive capabilities in malignant melanoma and outline their likely role in the future of melanoma staging, surveillance, and treatment.

Original languageEnglish (US)
Pages (from-to)473-483
Number of pages11
JournalJournal of Cellular Biochemistry
Issue number3
StatePublished - Oct 15 2005
Externally publishedYes


  • DNA
  • Melanoma
  • Molecular markers
  • qRT
  • RNA
  • RT-PCR

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology


Dive into the research topics of 'Molecular markers in malignant cutaneous melanoma: Gift horse or one-trick pony?'. Together they form a unique fingerprint.

Cite this